Unfortunately, I do not know of any studies comparing Xytiga and Erleada, but to be fair, I haven't needed to look. If there are any, they would have to be for your specific situation: localised or (oligo-)metastatic, castrate-sensitive or castrate resistant.

Erleada is the first ARSI they put me on (olgo-metastatic, castrate-sensitive), and together with emergency debulking surgery to the metastasis site on my spine, radiation and ADT, it's held my PSA at < 0.01 on the sensitive test for over 2½ years now, so my onco team and I haven't talked about any alternatives.

My radiation oncologist says that I'm in "remission", but I'd add a footnote that it's *medically-induced* remission — I don't know what would happen if I stopped the ADT and ARSI, and since I'm tolerating them well and living almost a normal, active life, I'm not interested in taking the risk of finding out.

In further reading, I've discovered that not all ARSIs have been approved for metastatic castrate-sensitive prostate cancer yet. I'm not sure of all the options, but that's one reason I'm on Erleada (the TITAN study demonstrated its efficacy for mCSPC).

Erleada isn't cheap. In Canada, it would cost close around US $4,000/month if I had to pay for it myself, which is eye-watering (by comparison, Firmagon or Orgovyx would cost about US $400/month if I had to pay). But I am convinced that it's one of the reasons my outlook for a long(er) life is so good right now, three years in.